A latex agglutination test for determination of antibody against cytomegalovirus was compared with five other methods: a solid-phase fluorescent immunoassay, an indirect hemagglutination test, two solid-phase enzyme immunoassays, and an indirect fluorescent-antibody method, with sera collected from 210 random blood donors. Of the sera tested, 28% were positive for anti-cytomegalovirus by concordance of four or more methods. The latex agglutination test performed well, with a sensitivity of 100%, a specificity of 99%, and positive and negative predictive values of 97 and 100%, respectively. The methods were also evaluated for the number of sera requiring repeat testing, equivocal results after retesting, ease of performance, turnaround time, and technical demands. The tests which best met the requirements for a screening test were the solid-phase fluorescent immunoassay, the indirect hemagglutination test, and the latex agglutination test. The latex agglutination test is a valuable screening tool for detecting total anti-cytomegalovirus which has high sensitivity, high negative predictive value, and rare equivocal results and also has the added advantages of ease of performance and rapid turnaround time.
The cytomegalovirus (CMV) antibody status of a transfusion or transplant candidate and that of the donor blood component or tissue may play a critical role in the management of at-risk patients such as low-birth-weight neonates and bone marrow or kidney transplant recipients (1-3, 12, 13, 18, 19) . Previous reports have compared a variety of methods for this determination (5, 6, 10, 11, 15, 16 Ideally, a method used to screen patients and potential blood components should (i) have a high sensitivity so that no positive sample is missed, (ii) have a high negative predictive value to establish confidence for blood component selection, (iii) exhibit minimal equivocal results requiring retesting or exclusion of potentially seronegative blood components, and (iv) be cost-effective as determined by each user.
The LA method ranks high when compared with other methods by these criteria. In this study, the FIAX system correctly categorized the seroreactivity of all specimens. The IHA method also demonstrated 100% sensitivity and negative predictive values.
The LA method is the only method tested which examines sera without dilution. The two false-positive LA tests, when quantitated, were positive only in the undiluted specimen in one case and at a titer of 1:2 in the second. It is difficult to assess the significance of agglutination at these low titers. The preparation of the sera for testing in the other methods excludes detection of such low titers. Spontaneous nonspecific agglutination of latex has been described with sera which are grossly lipemic or contaminated with bacteria (8) . Neither of these sera was grossly lipemic in appearance, nor was there evidence of bacterial contamination upon culture.
LA methods have been reported to be highly sensitive to changes in antibody or antigen levels during infection (9, 14, 17). It may be that these false-positive results by LA reflect a higher degree of sensitivity than found with the other methods rather than nonspecific agglutination. The two sera in question may indeed have contained low levels of anti-CMV. The clinical significance of such low levels of anti-CMV deserves further investigation.
The use of concordance as the basis for seroreactivity has resulted in sensitivities and specificities less than those reported elsewhere for certain methods. If those specimens which remained equivocal in this study were eliminated or placed subjectively in a seropositive or seronegative class, then performance results would improve, e.g., the specificity of the IHA method would increase to 94%. These sera were considered uninterpretable in this study, resulting in the exclusion of these blood components for use in transfusing the at-risk recipient.
From an implementation standpoint, the LA method offers distinct advantages in being the most rapid test and requiring only a 100-rpm rotator which many, if not most, serology laboratories already possess. The reading of the test is subjective. However, in our study, only four samples required repeat testing due to questionable agglutination. All methods tested produced some results which required repeating. This occurred with 3 samples tested by EIA (Abbott) (1%), 4 by FIA (2%), 13 by EIA (MA Bioproducts) (6%), 23 by IFA (11%), and 30 by IHA (14%). All the results, except those listed as equivocal, were resolved upon repeat testing. Thus, a repeat rate of 2% (4 of 209) for the LA method is not unexpected or unreasonable.
The decision to screen blood for anti-CMV or other markers of infectious risk rests with the needs of the community and the donor population characteristics of a region (K. Alpaugh, D. G. Beckwith, A. Schweder, and D. Blount-Fronefield, manuscript in preparation). When the decision is made to do such screening, the LA method offers a simple and rapid method with minimal need to purchase equipment. It ranks high in those characteristics essential for a good screening test: high sensitivity, high negative predictive value, and a low incidence of equivocal results.
